Studies for the Guidance of Safety Pharmacology Studies in Compliance with Good Laboratory Practice

被引：0

作者：

Choi, Ki Hwan ^{[1
]}

Park, Ki Sook ^{[1
]}

Lee, Yun Hee ^{[1
]}

Na, Hang-Kwang ^{[1
]}

Yun, Jae Suk ^{[1
]}

Kim, Dong-Sup ^{[1
]}

Kim, Joo-Il ^{[1
]}

机构：

[1] Korea Food & Drug Adm, Pharmacol Res Dept, Natl Inst Toxicol Res, Seoul 122704, South Korea

来源：

TOXICOLOGICAL RESEARCH | 2006年 / 22卷 / 02期

关键词：

Safety pharmacology; GLP; ICH;

D O I：

暂无

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

Safety pharmacology studies are conducted to investigated the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above. In the International Conference on Harmonisation (ICH),the guideline "S7A : Safety Pharmacology Studies for Human Pharmaceuticals" has been developed and reached Step 5 of the ICH process in 2001. Now the Korea Food and Drug Administration (KFDA) are going to transfer "The Guideline for General Pharmacology" into "The Guideline for Safety Pharmacology". Safety pharmacology studies should be performed in compliance with Good Laboratory Practice (GLP). Thus, the present paper reviews the Japanese GLP guidelines for pharmaceuticals to help the conduct and inspection of safety pharmacology studies in compliance with GLP. We also reviewed the ICH guidelines "S7B revised : The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals" and "E14 : The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs" to apply our drug approval systems.

引用

页码：109 / 116

页数：8

共 12 条

[1] Cavero Icilio, 2005, Expert Opin Drug Saf, V4, P509, DOI 10.1517/14740338.4.3.509
[2] Friedrichs Gregory S., 2005, Journal of Pharmacological and Toxicological Methods, V52, P6, DOI 10.1016/j.vascn.2005.05.001
[3] Gallo M. A, 2001, HIST SCOPE TOXICOLOG, P3
[4] ICH Harmonized Tripartite Guideline, 1997, PRECL SAF EV BIOT DE
[5] ICH Harmonized Tripartite Guideline, 2005, NONCL EV POT DEL VEN
[6] ICH Harmonized Tripartite Guideline, 2005, CLIN EV QT QTC INT P
[7] ICH Harmonized Tripartite Guideline, 1997, TIM NONCL SAF STUD C
[8] ICH Harmonized Tripartite Guideline (S7A), 2001, SAF PHARM STUD HUM P
[9] Cardiotoxicity of new antihistamines and cisapride
Paakkari, I
[J]. TOXICOLOGY LETTERS, 2002, 127 (1-3) : 279 - 284
[10] Drugs, QTc interval prolongation and final ICH E14 guideline - An important milestone with challenges ahead
Shah, RR
[J]. DRUG SAFETY, 2005, 28 (11) : 1009 - 1028

← 1 2 →